PRQR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ProQR Therapeutics NV (PRQR) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some positive momentum, the lack of significant trading trends, weak financial performance, and absence of strong catalysts make it prudent to hold off on investing in this stock right now.
The MACD histogram is positive at 0.0301 and expanding, indicating bullish momentum. RSI is at 72.216, which is neutral but approaching overbought territory. Moving averages are converging, suggesting indecision. Key resistance levels are at 1.572 and 1.636, with support at 1.366 and 1.302. The pre-market price of 1.615 is near R2, indicating limited upside potential in the short term.
The MACD and gross margin of 100% are positive indicators. Additionally, the stock is trading near resistance levels, which could attract short-term traders.
There is no recent news or significant trading trends from hedge funds or insiders. The lack of congress trading data and weak options activity further indicate limited interest in the stock.
In Q3 2025, revenue dropped to $2.915M (-26.78% YoY), while net income improved to -$11.006M (+35.74% YoY). EPS remained flat at -0.1, and gross margin stayed at 100%. Overall, financial performance shows some improvement in losses but declining revenue is a concern.
No data available for analyst ratings or price target changes.
